Drugs / TQB3820
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05020639 | Aug 2021 → Aug 2024 | hematopoietic and lymphoid cell neoplasm | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TQB3820 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05020639 ↗ |
| Route | Oral | “TQB3820 tablets are administrated orally on Days 1-28 of each 28-day treatment cycle.” NCT05020639 ↗ |
| Target | IKZF1 | “degradation of the hematopoietic transcription factors Ikaros (IKZF1) and Aiolos (IKZF3)” NCT05020639 ↗ |
| Target | IKZF3 | “degradation of the hematopoietic transcription factors Ikaros (IKZF1) and Aiolos (IKZF3)” NCT05020639 ↗ |